Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2022-02-20

AUTHORS

Russel J. Reiter, Ramaswamy Sharma, Fedor Simko, Alberto Dominguez-Rodriguez, Jan Tesarik, Richard L. Neel, Andrzej T. Slominski, Konrad Kleszczynski, Verna M. Martin-Gimenez, Walter Manucha, Daniel P. Cardinali

ABSTRACT

Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2. More... »

PAGES

143

References to SciGraph publications

  • 2021-10-02. Current trends in diagnosis and treatment strategies of COVID-19 infection in ENVIRONMENTAL SCIENCE AND POLLUTION RESEARCH
  • 2001-12. Effects of Melatonin Treatment in Septic Newborns in PEDIATRIC RESEARCH
  • 2021-11-22. Evaluation of the effect of clinical characteristics and intensive care treatment methods on the mortality of covid-19 patients aged 80 years and older in BMC ANESTHESIOLOGY
  • 2019-03-12. Crotoxin promotes macrophage reprogramming towards an antiangiogenic phenotype in SCIENTIFIC REPORTS
  • 2020-08-18. Pharmacogenomics of COVID-19 therapies in NPJ GENOMIC MEDICINE
  • 2021-06-08. Secretory Phospholipase A2 Enzymes in Acute Lung Injury in CELL BIOCHEMISTRY AND BIOPHYSICS
  • 2021-08-04. Perimyocarditis following first dose of the mRNA-1273 SARS-CoV-2 (Moderna) vaccine in a healthy young male: a case report in BMC CARDIOVASCULAR DISORDERS
  • 1999. Therapeutic Potential of Melatonin in Immunodeficiency States, Viral Diseases, and Cancer in TRYPTOPHAN, SEROTONIN, AND MELATONIN
  • 2021-04-05. Mechanistic insight on the role of leukotriene receptors in ischemic–reperfusion injury in PHARMACOLOGICAL REPORTS
  • 2021-05-24. Estimates of gene ensemble noise highlight critical pathways and predict disease severity in H1N1, COVID-19 and mortality in sepsis patients in SCIENTIFIC REPORTS
  • 2017-08-08. Melatonin, mitochondria and hypertension in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2020-01-22. Melatonin inhibits Warburg-dependent cancer by redirecting glucose oxidation to the mitochondria: a mechanistic hypothesis in CELLULAR AND MOLECULAR LIFE SCIENCES
  • 2021-09-01. Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development in SIGNAL TRANSDUCTION AND TARGETED THERAPY
  • 2021-09-09. Cardiovascular magnetic resonance findings in young adult patients with acute myocarditis following mRNA COVID-19 vaccination: a case series in JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
  • 2018-07-25. Current status of laboratory and imaging diagnosis of neonatal necrotizing enterocolitis in ITALIAN JOURNAL OF PEDIATRICS
  • 2020-05-06. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages in NATURE REVIEWS IMMUNOLOGY
  • 2021-10-14. Brain MRI in SARS-CoV-2 pneumonia patients with newly developed neurological manifestations suggestive of brain involvement in SCIENTIFIC REPORTS
  • 2021-10-14. Targeting the complex I and III of mitochondrial electron transport chain as a potentially viable option in liver cancer management in CELL DEATH DISCOVERY
  • 2021-08-18. HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19 in SIGNAL TRANSDUCTION AND TARGETED THERAPY
  • 2021-09-08. Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics in SCIENTIFIC REPORTS
  • 2021-08-30. COVID-19: potential therapeutics for pediatric patients in PHARMACOLOGICAL REPORTS
  • 2019-10-23. Metabolic regulation of gene expression by histone lactylation in NATURE
  • 2007-01. Effects of melatonin onCandida sepsis in an experimental rat model in ADVANCES IN THERAPY
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1007/s00018-021-04102-3

    DOI

    http://dx.doi.org/10.1007/s00018-021-04102-3

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1145723773

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/35187603


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1108", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical Microbiology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1115", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Pharmacology and Pharmaceutical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antioxidants", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Antiviral Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "COVID-19", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Melatonin", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "SARS-CoV-2", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.43582.38", 
              "name": [
                "Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Reiter", 
            "givenName": "Russel J.", 
            "id": "sg:person.01355263250.54", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355263250.54"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.43582.38", 
              "name": [
                "Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Sharma", 
            "givenName": "Ramaswamy", 
            "id": "sg:person.07347561163.03", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07347561163.03"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic", 
              "id": "http://www.grid.ac/institutes/grid.7634.6", 
              "name": [
                "Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Simko", 
            "givenName": "Fedor", 
            "id": "sg:person.014536145054.45", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014536145054.45"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain", 
              "id": "http://www.grid.ac/institutes/grid.411220.4", 
              "name": [
                "Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Dominguez-Rodriguez", 
            "givenName": "Alberto", 
            "id": "sg:person.0752145771.64", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752145771.64"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MARGen Clinic, 18006, Granada, Spain", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "MARGen Clinic, 18006, Granada, Spain"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tesarik", 
            "givenName": "Jan", 
            "id": "sg:person.0644327760.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644327760.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "CEO, Alcasian Care Enterprises, Castroville, TX, USA", 
              "id": "http://www.grid.ac/institutes/None", 
              "name": [
                "CEO, Alcasian Care Enterprises, Castroville, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Neel", 
            "givenName": "Richard L.", 
            "id": "sg:person.016426350020.09", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016426350020.09"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, USA", 
              "id": "http://www.grid.ac/institutes/grid.280808.a", 
              "name": [
                "Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA", 
                "Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Slominski", 
            "givenName": "Andrzej T.", 
            "id": "sg:person.016612034677.24", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016612034677.24"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Dermatology, University of M\u00fcnster, M\u00fcnster, Germany", 
              "id": "http://www.grid.ac/institutes/grid.5949.1", 
              "name": [
                "Department of Dermatology, University of M\u00fcnster, M\u00fcnster, Germany"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Kleszczynski", 
            "givenName": "Konrad", 
            "id": "sg:person.0636142753.57", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636142753.57"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Instituto de Investigaciones en Ciencias Qu\u00edmicas, Facultad de Cs. Qu\u00edmicas Y Tecnol\u00f3gicas, Universidad Cat\u00f3lica de Cuyo, San Juan, Argentina", 
              "id": "http://www.grid.ac/institutes/grid.430658.c", 
              "name": [
                "Instituto de Investigaciones en Ciencias Qu\u00edmicas, Facultad de Cs. Qu\u00edmicas Y Tecnol\u00f3gicas, Universidad Cat\u00f3lica de Cuyo, San Juan, Argentina"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Martin-Gimenez", 
            "givenName": "Verna M.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "\u00c1rea de Farmacolog\u00eda, Departamento de Patolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de Cuyo, Mendoza, Argentina", 
              "id": "http://www.grid.ac/institutes/grid.412108.e", 
              "name": [
                "Instituto de Investigaciones en Ciencias Qu\u00edmicas, Facultad de Cs. Qu\u00edmicas Y Tecnol\u00f3gicas, Universidad Cat\u00f3lica de Cuyo, San Juan, Argentina", 
                "\u00c1rea de Farmacolog\u00eda, Departamento de Patolog\u00eda, Facultad de Ciencias M\u00e9dicas, Universidad Nacional de Cuyo, Mendoza, Argentina"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Manucha", 
            "givenName": "Walter", 
            "id": "sg:person.01261621367.22", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261621367.22"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Faculty of Medical Sciences, Pontificia Universidad Cat\u00f3lica Argentina, Buenos Aires, Argentina", 
              "id": "http://www.grid.ac/institutes/grid.412525.5", 
              "name": [
                "Faculty of Medical Sciences, Pontificia Universidad Cat\u00f3lica Argentina, Buenos Aires, Argentina"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Cardinali", 
            "givenName": "Daniel P.", 
            "id": "sg:person.01332176417.86", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332176417.86"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1186/s12968-021-00795-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140978708", 
              "https://doi.org/10.1186/s12968-021-00795-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1203/00006450-200112000-00021", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051547199", 
              "https://doi.org/10.1203/00006450-200112000-00021"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13052-018-0528-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1105837245", 
              "https://doi.org/10.1186/s13052-018-0528-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s12013-021-01003-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138692234", 
              "https://doi.org/10.1007/s12013-021-01003-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12872-021-02183-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140178312", 
              "https://doi.org/10.1186/s12872-021-02183-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-019-03438-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1124225619", 
              "https://doi.org/10.1007/s00018-019-03438-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/978-1-4615-4709-9_28", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003019301", 
              "https://doi.org/10.1007/978-1-4615-4709-9_28"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41392-021-00726-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140491571", 
              "https://doi.org/10.1038/s41392-021-00726-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-021-00064-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141875412", 
              "https://doi.org/10.1038/s41598-021-00064-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-021-97160-3", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140968949", 
              "https://doi.org/10.1038/s41598-021-97160-3"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41420-021-00675-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141879590", 
              "https://doi.org/10.1038/s41420-021-00675-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41586-019-1678-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1122022956", 
              "https://doi.org/10.1038/s41586-019-1678-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s43440-021-00258-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136928424", 
              "https://doi.org/10.1007/s43440-021-00258-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00018-017-2613-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091100688", 
              "https://doi.org/10.1007/s00018-017-2613-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02849996", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017491503", 
              "https://doi.org/10.1007/bf02849996"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s12871-021-01511-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1142714937", 
              "https://doi.org/10.1186/s12871-021-01511-6"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41577-020-0331-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1127402627", 
              "https://doi.org/10.1038/s41577-020-0331-4"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41525-020-00143-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1130158787", 
              "https://doi.org/10.1038/s41525-020-00143-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s43440-021-00316-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140731330", 
              "https://doi.org/10.1007/s43440-021-00316-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41392-021-00745-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1140801889", 
              "https://doi.org/10.1038/s41392-021-00745-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-021-90192-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1138295003", 
              "https://doi.org/10.1038/s41598-021-90192-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s11356-021-16715-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1141599860", 
              "https://doi.org/10.1007/s11356-021-16715-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-019-40903-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1112706546", 
              "https://doi.org/10.1038/s41598-019-40903-0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2022-02-20", 
        "datePublishedReg": "2022-02-20", 
        "description": "Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin\u2019s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.", 
        "genre": "article", 
        "id": "sg:pub.10.1007/s00018-021-04102-3", 
        "isAccessibleForFree": true, 
        "isPartOf": [
          {
            "id": "sg:journal.1295005", 
            "issn": [
              "1420-682X", 
              "1420-9071"
            ], 
            "name": "Cellular and Molecular Life Sciences", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "3", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "79"
          }
        ], 
        "keywords": [
          "SARS-CoV-2 infection", 
          "SARS-CoV-2", 
          "duration of hospitalization", 
          "COVID-19 patients", 
          "anti-inflammatory agents", 
          "high safety profile", 
          "use of melatonin", 
          "severity of infection", 
          "COVID-19 disease", 
          "safety profile", 
          "serious condition", 
          "prophylactic agent", 
          "beneficial drugs", 
          "side effects", 
          "viral infection", 
          "useful agent", 
          "potential treatment", 
          "melatonin's ability", 
          "infection", 
          "effective agent", 
          "significant toxicity", 
          "death rate", 
          "melatonin", 
          "high efficacy", 
          "drugs", 
          "lack toxicity", 
          "hospitalization", 
          "death of animals", 
          "COVID-19", 
          "different viruses", 
          "treatment", 
          "disease", 
          "different coronaviruses", 
          "severity", 
          "numerous pharmaceutical drugs", 
          "toxicity", 
          "agents", 
          "pharmaceutical drugs", 
          "medications", 
          "patients", 
          "doses", 
          "efficacy", 
          "death", 
          "virus", 
          "coronavirus", 
          "duration", 
          "animals", 
          "use", 
          "molecular processes", 
          "effect", 
          "pandemic", 
          "humans", 
          "exhaustion", 
          "rationale", 
          "ability", 
          "publications", 
          "rate", 
          "profile", 
          "need", 
          "combination", 
          "network analysis", 
          "conditions", 
          "degree", 
          "analysis", 
          "scientific publications", 
          "authors", 
          "wide range", 
          "consideration", 
          "countermeasures", 
          "range", 
          "process"
        ], 
        "name": "Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection", 
        "pagination": "143", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1145723773"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1007/s00018-021-04102-3"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "35187603"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1007/s00018-021-04102-3", 
          "https://app.dimensions.ai/details/publication/pub.1145723773"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-09-02T16:06", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_924.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1007/s00018-021-04102-3"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00018-021-04102-3'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00018-021-04102-3'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00018-021-04102-3'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00018-021-04102-3'


     

    This table displays all metadata directly associated to this object as RDF triples.

    349 TRIPLES      21 PREDICATES      126 URIs      94 LITERALS      13 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1007/s00018-021-04102-3 schema:about N4286dfcb8f70409ab3152692f83da4b5
    2 N4a04e67d858a4f9992bd4dbf0b2ade2e
    3 N7ade2fe400d348c9bcca14b5c688289a
    4 N9e226cf3eefe418e84d8e60f653ef8ae
    5 Na99f034c9b564e04a5f6c967368bfe7f
    6 Nab73cc7086444597b7ec7b610094756e
    7 anzsrc-for:11
    8 anzsrc-for:1108
    9 anzsrc-for:1115
    10 schema:author Ne25857d8088749059f7a3cd33b60074b
    11 schema:citation sg:pub.10.1007/978-1-4615-4709-9_28
    12 sg:pub.10.1007/bf02849996
    13 sg:pub.10.1007/s00018-017-2613-y
    14 sg:pub.10.1007/s00018-019-03438-1
    15 sg:pub.10.1007/s11356-021-16715-z
    16 sg:pub.10.1007/s12013-021-01003-x
    17 sg:pub.10.1007/s43440-021-00258-8
    18 sg:pub.10.1007/s43440-021-00316-1
    19 sg:pub.10.1038/s41392-021-00726-w
    20 sg:pub.10.1038/s41392-021-00745-7
    21 sg:pub.10.1038/s41420-021-00675-x
    22 sg:pub.10.1038/s41525-020-00143-y
    23 sg:pub.10.1038/s41577-020-0331-4
    24 sg:pub.10.1038/s41586-019-1678-1
    25 sg:pub.10.1038/s41598-019-40903-0
    26 sg:pub.10.1038/s41598-021-00064-5
    27 sg:pub.10.1038/s41598-021-90192-9
    28 sg:pub.10.1038/s41598-021-97160-3
    29 sg:pub.10.1186/s12871-021-01511-6
    30 sg:pub.10.1186/s12872-021-02183-3
    31 sg:pub.10.1186/s12968-021-00795-4
    32 sg:pub.10.1186/s13052-018-0528-3
    33 sg:pub.10.1203/00006450-200112000-00021
    34 schema:datePublished 2022-02-20
    35 schema:datePublishedReg 2022-02-20
    36 schema:description Numerous pharmaceutical drugs have been repurposed for use as treatments for COVID-19 disease. These drugs have not consistently demonstrated high efficacy in preventing or treating this serious condition and all have side effects to differing degrees. We encourage the continued consideration of the use of the antioxidant and anti-inflammatory agent, melatonin, as a countermeasure to a SARS-CoV-2 infection. More than 140 scientific publications have identified melatonin as a likely useful agent to treat this disease. Moreover, the publications cited provide the rationale for the use of melatonin as a prophylactic agent against this condition. Melatonin has pan-antiviral effects and it diminishes the severity of viral infections and reduces the death of animals infected with numerous different viruses, including three different coronaviruses. Network analyses, which compared drugs used to treat SARS-CoV-2 in humans, also predicted that melatonin would be the most effective agent for preventing/treating COVID-19. Finally, when seriously infected COVID-19 patients were treated with melatonin, either alone or in combination with other medications, these treatments reduced the severity of infection, lowered the death rate, and shortened the duration of hospitalization. Melatonin’s ability to arrest SARS-CoV-2 infections may reduce health care exhaustion by limiting the need for hospitalization. Importantly, melatonin has a high safety profile over a wide range of doses and lacks significant toxicity. Some molecular processes by which melatonin resists a SARS-CoV-2 infection are summarized. The authors believe that all available, potentially beneficial drugs, including melatonin, that lack toxicity should be used in pandemics such as that caused by SARS-CoV-2.
    37 schema:genre article
    38 schema:isAccessibleForFree true
    39 schema:isPartOf N01bcdf93fae74d82b6bdc460d0c40fbd
    40 Nd2a854cc8c774f1f96116d7e6e6f1023
    41 sg:journal.1295005
    42 schema:keywords COVID-19
    43 COVID-19 disease
    44 COVID-19 patients
    45 SARS-CoV-2
    46 SARS-CoV-2 infection
    47 ability
    48 agents
    49 analysis
    50 animals
    51 anti-inflammatory agents
    52 authors
    53 beneficial drugs
    54 combination
    55 conditions
    56 consideration
    57 coronavirus
    58 countermeasures
    59 death
    60 death of animals
    61 death rate
    62 degree
    63 different coronaviruses
    64 different viruses
    65 disease
    66 doses
    67 drugs
    68 duration
    69 duration of hospitalization
    70 effect
    71 effective agent
    72 efficacy
    73 exhaustion
    74 high efficacy
    75 high safety profile
    76 hospitalization
    77 humans
    78 infection
    79 lack toxicity
    80 medications
    81 melatonin
    82 melatonin's ability
    83 molecular processes
    84 need
    85 network analysis
    86 numerous pharmaceutical drugs
    87 pandemic
    88 patients
    89 pharmaceutical drugs
    90 potential treatment
    91 process
    92 profile
    93 prophylactic agent
    94 publications
    95 range
    96 rate
    97 rationale
    98 safety profile
    99 scientific publications
    100 serious condition
    101 severity
    102 severity of infection
    103 side effects
    104 significant toxicity
    105 toxicity
    106 treatment
    107 use
    108 use of melatonin
    109 useful agent
    110 viral infection
    111 virus
    112 wide range
    113 schema:name Melatonin: highlighting its use as a potential treatment for SARS-CoV-2 infection
    114 schema:pagination 143
    115 schema:productId N101949a221fd454386cc6ba6454fc8d1
    116 N30b7dc83fe7f44e0b5288f9c1cd89bc9
    117 Ne61447b7486843b0b29d37ac9a8660ab
    118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1145723773
    119 https://doi.org/10.1007/s00018-021-04102-3
    120 schema:sdDatePublished 2022-09-02T16:06
    121 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    122 schema:sdPublisher Ne29267c5c59f432489bc732e53dcb118
    123 schema:url https://doi.org/10.1007/s00018-021-04102-3
    124 sgo:license sg:explorer/license/
    125 sgo:sdDataset articles
    126 rdf:type schema:ScholarlyArticle
    127 N01bcdf93fae74d82b6bdc460d0c40fbd schema:issueNumber 3
    128 rdf:type schema:PublicationIssue
    129 N101949a221fd454386cc6ba6454fc8d1 schema:name pubmed_id
    130 schema:value 35187603
    131 rdf:type schema:PropertyValue
    132 N17cb87e2d5df45679956765abfed7024 rdf:first sg:person.0636142753.57
    133 rdf:rest Ne564f4e669fc4e249126f425a3207cf8
    134 N18488669783e4b73b9afa59ec1a439e1 rdf:first sg:person.01261621367.22
    135 rdf:rest Na305502f0e45483a94c737445d574d0a
    136 N30b7dc83fe7f44e0b5288f9c1cd89bc9 schema:name dimensions_id
    137 schema:value pub.1145723773
    138 rdf:type schema:PropertyValue
    139 N33359d05ccaa426bb11d6c0ff4e099fb rdf:first sg:person.014536145054.45
    140 rdf:rest Ncbe27af43caa49b7aec5f5e7d0e49ce3
    141 N3c658d2cb2a24ec2b654c02fbf66f088 schema:affiliation grid-institutes:grid.430658.c
    142 schema:familyName Martin-Gimenez
    143 schema:givenName Verna M.
    144 rdf:type schema:Person
    145 N3de367535af04497bf62b439dbbd27cb rdf:first sg:person.07347561163.03
    146 rdf:rest N33359d05ccaa426bb11d6c0ff4e099fb
    147 N4286dfcb8f70409ab3152692f83da4b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    148 schema:name Melatonin
    149 rdf:type schema:DefinedTerm
    150 N4a04e67d858a4f9992bd4dbf0b2ade2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    151 schema:name Antioxidants
    152 rdf:type schema:DefinedTerm
    153 N7ade2fe400d348c9bcca14b5c688289a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    154 schema:name SARS-CoV-2
    155 rdf:type schema:DefinedTerm
    156 N9e226cf3eefe418e84d8e60f653ef8ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Antiviral Agents
    158 rdf:type schema:DefinedTerm
    159 Na305502f0e45483a94c737445d574d0a rdf:first sg:person.01332176417.86
    160 rdf:rest rdf:nil
    161 Na99f034c9b564e04a5f6c967368bfe7f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    162 schema:name Humans
    163 rdf:type schema:DefinedTerm
    164 Nab73cc7086444597b7ec7b610094756e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    165 schema:name COVID-19
    166 rdf:type schema:DefinedTerm
    167 Ncbe27af43caa49b7aec5f5e7d0e49ce3 rdf:first sg:person.0752145771.64
    168 rdf:rest Nf4201a18920840528a4d822b30298950
    169 Nd2a854cc8c774f1f96116d7e6e6f1023 schema:volumeNumber 79
    170 rdf:type schema:PublicationVolume
    171 Nddbeb7e38cea4c9aa58120aeebb05a84 rdf:first sg:person.016612034677.24
    172 rdf:rest N17cb87e2d5df45679956765abfed7024
    173 Ne1c2b6d121aa4d8087b480316082c803 rdf:first sg:person.016426350020.09
    174 rdf:rest Nddbeb7e38cea4c9aa58120aeebb05a84
    175 Ne25857d8088749059f7a3cd33b60074b rdf:first sg:person.01355263250.54
    176 rdf:rest N3de367535af04497bf62b439dbbd27cb
    177 Ne29267c5c59f432489bc732e53dcb118 schema:name Springer Nature - SN SciGraph project
    178 rdf:type schema:Organization
    179 Ne564f4e669fc4e249126f425a3207cf8 rdf:first N3c658d2cb2a24ec2b654c02fbf66f088
    180 rdf:rest N18488669783e4b73b9afa59ec1a439e1
    181 Ne61447b7486843b0b29d37ac9a8660ab schema:name doi
    182 schema:value 10.1007/s00018-021-04102-3
    183 rdf:type schema:PropertyValue
    184 Nf4201a18920840528a4d822b30298950 rdf:first sg:person.0644327760.24
    185 rdf:rest Ne1c2b6d121aa4d8087b480316082c803
    186 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    187 schema:name Medical and Health Sciences
    188 rdf:type schema:DefinedTerm
    189 anzsrc-for:1108 schema:inDefinedTermSet anzsrc-for:
    190 schema:name Medical Microbiology
    191 rdf:type schema:DefinedTerm
    192 anzsrc-for:1115 schema:inDefinedTermSet anzsrc-for:
    193 schema:name Pharmacology and Pharmaceutical Sciences
    194 rdf:type schema:DefinedTerm
    195 sg:journal.1295005 schema:issn 1420-682X
    196 1420-9071
    197 schema:name Cellular and Molecular Life Sciences
    198 schema:publisher Springer Nature
    199 rdf:type schema:Periodical
    200 sg:person.01261621367.22 schema:affiliation grid-institutes:grid.412108.e
    201 schema:familyName Manucha
    202 schema:givenName Walter
    203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01261621367.22
    204 rdf:type schema:Person
    205 sg:person.01332176417.86 schema:affiliation grid-institutes:grid.412525.5
    206 schema:familyName Cardinali
    207 schema:givenName Daniel P.
    208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332176417.86
    209 rdf:type schema:Person
    210 sg:person.01355263250.54 schema:affiliation grid-institutes:grid.43582.38
    211 schema:familyName Reiter
    212 schema:givenName Russel J.
    213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01355263250.54
    214 rdf:type schema:Person
    215 sg:person.014536145054.45 schema:affiliation grid-institutes:grid.7634.6
    216 schema:familyName Simko
    217 schema:givenName Fedor
    218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014536145054.45
    219 rdf:type schema:Person
    220 sg:person.016426350020.09 schema:affiliation grid-institutes:None
    221 schema:familyName Neel
    222 schema:givenName Richard L.
    223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016426350020.09
    224 rdf:type schema:Person
    225 sg:person.016612034677.24 schema:affiliation grid-institutes:grid.280808.a
    226 schema:familyName Slominski
    227 schema:givenName Andrzej T.
    228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016612034677.24
    229 rdf:type schema:Person
    230 sg:person.0636142753.57 schema:affiliation grid-institutes:grid.5949.1
    231 schema:familyName Kleszczynski
    232 schema:givenName Konrad
    233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0636142753.57
    234 rdf:type schema:Person
    235 sg:person.0644327760.24 schema:affiliation grid-institutes:None
    236 schema:familyName Tesarik
    237 schema:givenName Jan
    238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644327760.24
    239 rdf:type schema:Person
    240 sg:person.07347561163.03 schema:affiliation grid-institutes:grid.43582.38
    241 schema:familyName Sharma
    242 schema:givenName Ramaswamy
    243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07347561163.03
    244 rdf:type schema:Person
    245 sg:person.0752145771.64 schema:affiliation grid-institutes:grid.411220.4
    246 schema:familyName Dominguez-Rodriguez
    247 schema:givenName Alberto
    248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752145771.64
    249 rdf:type schema:Person
    250 sg:pub.10.1007/978-1-4615-4709-9_28 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003019301
    251 https://doi.org/10.1007/978-1-4615-4709-9_28
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1007/bf02849996 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017491503
    254 https://doi.org/10.1007/bf02849996
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1007/s00018-017-2613-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1091100688
    257 https://doi.org/10.1007/s00018-017-2613-y
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1007/s00018-019-03438-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124225619
    260 https://doi.org/10.1007/s00018-019-03438-1
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1007/s11356-021-16715-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1141599860
    263 https://doi.org/10.1007/s11356-021-16715-z
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1007/s12013-021-01003-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1138692234
    266 https://doi.org/10.1007/s12013-021-01003-x
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1007/s43440-021-00258-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1136928424
    269 https://doi.org/10.1007/s43440-021-00258-8
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1007/s43440-021-00316-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140731330
    272 https://doi.org/10.1007/s43440-021-00316-1
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1038/s41392-021-00726-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1140491571
    275 https://doi.org/10.1038/s41392-021-00726-w
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.1038/s41392-021-00745-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140801889
    278 https://doi.org/10.1038/s41392-021-00745-7
    279 rdf:type schema:CreativeWork
    280 sg:pub.10.1038/s41420-021-00675-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1141879590
    281 https://doi.org/10.1038/s41420-021-00675-x
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1038/s41525-020-00143-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1130158787
    284 https://doi.org/10.1038/s41525-020-00143-y
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1038/s41577-020-0331-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1127402627
    287 https://doi.org/10.1038/s41577-020-0331-4
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1038/s41586-019-1678-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1122022956
    290 https://doi.org/10.1038/s41586-019-1678-1
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1038/s41598-019-40903-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112706546
    293 https://doi.org/10.1038/s41598-019-40903-0
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1038/s41598-021-00064-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141875412
    296 https://doi.org/10.1038/s41598-021-00064-5
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1038/s41598-021-90192-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1138295003
    299 https://doi.org/10.1038/s41598-021-90192-9
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1038/s41598-021-97160-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140968949
    302 https://doi.org/10.1038/s41598-021-97160-3
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1186/s12871-021-01511-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1142714937
    305 https://doi.org/10.1186/s12871-021-01511-6
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1186/s12872-021-02183-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140178312
    308 https://doi.org/10.1186/s12872-021-02183-3
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1186/s12968-021-00795-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1140978708
    311 https://doi.org/10.1186/s12968-021-00795-4
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1186/s13052-018-0528-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1105837245
    314 https://doi.org/10.1186/s13052-018-0528-3
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1203/00006450-200112000-00021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051547199
    317 https://doi.org/10.1203/00006450-200112000-00021
    318 rdf:type schema:CreativeWork
    319 grid-institutes:None schema:alternateName CEO, Alcasian Care Enterprises, Castroville, TX, USA
    320 MARGen Clinic, 18006, Granada, Spain
    321 schema:name CEO, Alcasian Care Enterprises, Castroville, TX, USA
    322 MARGen Clinic, 18006, Granada, Spain
    323 rdf:type schema:Organization
    324 grid-institutes:grid.280808.a schema:alternateName Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, USA
    325 schema:name Department of Dermatology, University of Alabama at Birmingham, Birmingham, AL, USA
    326 Pathology and Laboratory Medicine Service, VA Medical Center, Birmingham, AL, USA
    327 rdf:type schema:Organization
    328 grid-institutes:grid.411220.4 schema:alternateName Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
    329 schema:name Department of Cardiology, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
    330 rdf:type schema:Organization
    331 grid-institutes:grid.412108.e schema:alternateName Área de Farmacología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina
    332 schema:name Instituto de Investigaciones en Ciencias Químicas, Facultad de Cs. Químicas Y Tecnológicas, Universidad Católica de Cuyo, San Juan, Argentina
    333 Área de Farmacología, Departamento de Patología, Facultad de Ciencias Médicas, Universidad Nacional de Cuyo, Mendoza, Argentina
    334 rdf:type schema:Organization
    335 grid-institutes:grid.412525.5 schema:alternateName Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina
    336 schema:name Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, Buenos Aires, Argentina
    337 rdf:type schema:Organization
    338 grid-institutes:grid.430658.c schema:alternateName Instituto de Investigaciones en Ciencias Químicas, Facultad de Cs. Químicas Y Tecnológicas, Universidad Católica de Cuyo, San Juan, Argentina
    339 schema:name Instituto de Investigaciones en Ciencias Químicas, Facultad de Cs. Químicas Y Tecnológicas, Universidad Católica de Cuyo, San Juan, Argentina
    340 rdf:type schema:Organization
    341 grid-institutes:grid.43582.38 schema:alternateName Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA
    342 schema:name Department of Cell Systems and Anatomy, UT Health San Antonio, Long School of Medicine, San Antonio, TX, USA
    343 rdf:type schema:Organization
    344 grid-institutes:grid.5949.1 schema:alternateName Department of Dermatology, University of Münster, Münster, Germany
    345 schema:name Department of Dermatology, University of Münster, Münster, Germany
    346 rdf:type schema:Organization
    347 grid-institutes:grid.7634.6 schema:alternateName Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic
    348 schema:name Institute of Pathophysiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic
    349 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...